The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
This approval is a significant achievement in expanding the availability of this critical therapeutic,
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Exploring new opportunities within the fast-growing market of microfluidics
Divestment is part of BASF’s strategic portfolio optimization
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
The company has received the GMP Certification after successful closure of the inspection
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
This facility marks a significant milestone in transforming the global food industr
Subscribe To Our Newsletter & Stay Updated
